Moderate to Severe Asthma

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443

Sponsor: Incyte Corporation

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.